Which gene variants predict whether sapropterin will work in PKU?
Sapropterin (BH4) response in phenylketonuria (PKU) mainly depends on variants in the phenylalanine hydroxylase pathway—especially the gene that encodes phenylalanine hydroxylase (PAH). Variants that leave PAH partially functional tend to respond better to BH4, because sapropterin can stabilize or improve the remaining enzymatic activity.
In contrast, variants that cause little or no functional PAH generally predict a poor response to sapropterin.
What role does PAH genotype play (and which variant types respond best)?
In practice, genotype-response patterns are described in terms of how much residual PAH activity a patient’s PAH mutations allow. Broadly:
- Mutations associated with some residual PAH activity are more likely to show meaningful decreases in blood phenylalanine on sapropterin.
- Mutations associated with absent or severely reduced PAH activity are less likely to lower phenylalanine with BH4 alone.
This PAH “residual activity” concept is the core genetic reason sapropterin works in some people and not others.
Do variants in anything other than PAH affect sapropterin response?
Genetic factors outside PAH can also influence response indirectly, but PAH genotype remains the dominant genetic predictor. Other genes in phenylalanine/biopterin biology can affect the system’s overall capacity to handle phenylalanine, yet the strongest, most consistently used genetic guidance for sapropterin responsiveness centers on PAH mutation type and residual enzyme function.
How do clinicians use genotype to decide on sapropterin trials?
Because genetic predictions are imperfect, clinical testing is commonly used to confirm response. Even with favorable PAH variants, clinicians still typically evaluate biochemical response with a supervised sapropterin trial before labeling someone as a non-responder, since factors like baseline diet, adherence, and individual biology can modify results.
What do “responders” and “non-responders” mean genetically?
Genetically, the responder group is enriched for PAH mutations that preserve partial enzyme activity. The non-responder group is enriched for PAH mutations that eliminate functional PAH. That genetic separation helps explain why sapropterin response correlates with certain mutation classes, even though it does not predict outcome perfectly for every individual.
Where can I check gene-linked response information?
For a drug-focused view of sapropterin in PKU (including labeling and related context), DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/ (site search for sapropterin/PKU).
Sources
No source documents were provided with your question, so I can’t cite specific studies or a definitive guideline table here. If you share the platform or guideline you want to align with (e.g., a specific paper, FDA/EMA label excerpt, or a genotype-response guideline), I can extract the exact genetic factors and cite them precisely.